GNH USA

Europe — EMA

Naos (Salbutamol Sulfate, Ipratropium Bromide)

GNH USA supplies Naos (Salbutamol/Ipratropium), a bronchodilator for asthma and COPD. Request a quote for global supply from our EU‑compliant facility.

Salbutamol Sulfate, Ipratropium Bromide

Request sourcing

1
Pack/s

What is Salbutamol Sulfate, Ipratropium Bromide?

Salbutamol sulfate / ipratropium bromide, the active ingredient in Naos, is a short‑acting β2‑agonist / anticholinergic combination presented as an inhalation solution for inhalation use. It provides bronchodilation for patients with asthma and chronic obstructive pulmonary disease.

GNH USA supplies Naos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Salbutamol Sulfate, Ipratropium Bromide used for?

Naos is a bronchodilator inhalation therapy used in respiratory disorders where airway constriction occurs.

- Asthma: rapidly relieves acute bronchospasm and improves airflow. - Chronic obstructive pulmonary disease (COPD) – maintenance: helps maintain open airways and reduces symptom frequency. - COPD – acute relief: provides quick bronchodilation during exacerbations.

What are the side effects of Salbutamol Sulfate, Ipratropium Bromide?

Adverse reactions may occur with inhalation of Naos.

Common Side Effects: - Tremor: mild shaking of hands or limbs. - Headache: transient cranial discomfort. - Throat irritation: dryness or soreness in the throat. - Cough: brief irritation‑induced coughing. - Dry mouth: reduced salivation. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Paradoxical bronchospasm: worsening airway narrowing. - Angioedema: swelling of face, lips, or tongue. - Tachycardia: abnormally fast heart rate. - Arrhythmia: irregular cardiac rhythm. - Hypokalemia: low blood potassium levels. - Severe allergic reaction: anaphylaxis requiring emergency care.

What precautions apply to Salbutamol Sulfate, Ipratropium Bromide?

Before prescribing Naos, consider patient‑specific factors and safety measures.

- Cardiovascular disease: monitor for tachycardia or arrhythmias. - Thyroid disorders: use with caution in hyperthyroidism. - Diabetes: observe possible glucose fluctuations. - Elderly patients: start with the lowest effective dose. - Concomitant β‑agonists: avoid excessive β2‑stimulation. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

What does Salbutamol Sulfate, Ipratropium Bromide interact with?

Naos may interact with other medications; assess risk before co‑administration.

Major Interactions (Avoid): - Non‑selective β‑blockers: can diminish bronchodilator effect and precipitate bronchospasm. - Monoamine oxidase inhibitors (MAOIs): may increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Other β2‑agonists: risk of additive tachycardia. - Diuretics: monitor serum potassium levels. - Anticholinergic drugs: may enhance dry‑mouth or urinary retention. - Theophylline: observe for increased theophylline toxicity.

Frequently asked questions

What conditions is Naos used to treat?+
Naos is prescribed for patients with asthma to relieve acute bronchospasm and for those with chronic obstructive pulmonary disease (COPD) both as a maintenance therapy and for rapid relief during exacerbations. It helps open narrowed airways, improving breathing and reducing symptoms such as wheezing and shortness of breath.
How does the combination of salbutamol and ipratropium work in Naos?+
Salbutamol activates β2‑adrenergic receptors on airway smooth muscle, causing relaxation, while ipratropium blocks muscarinic receptors, preventing acetylcholine‑induced constriction. Together they provide a synergistic bronchodilatory effect, quickly widening the airways and enhancing airflow in obstructive lung conditions.
What is the usual dose of Naos?+
The specific dose and frequency of Naos are determined by the prescribing clinician based on the patient’s age, severity of disease, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal bronchodilation while minimizing potential side effects.
Is Naos safe to use during pregnancy or breastfeeding?+
Safety data for Naos in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss individual circumstances and consider alternative therapies when appropriate.
How do I order Naos from GNH USA?+
To request Naos, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.
How does Naos compare with other bronchodilator options?+
Naos combines a short‑acting β2‑agonist (salbutamol) with an anticholinergic (ipratropium), offering dual mechanisms that can be more effective than single‑agent inhalers for certain patients. Compared with monotherapy β2‑agonists, the combination may provide faster relief and reduce the need for higher doses, while having a safety profile similar to other inhaled bronchodilators.
What are the storage and handling requirements for Naos?+
Naos should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the inhalation device upright and ensure the mouthpiece is clean before each use. Do not freeze the solution, and discard any product that appears discolored or contaminated.
How is Naos administered to patients?+
Naos is delivered via a metered‑dose inhaler or nebulizer, depending on the formulation supplied. The patient inhales the prescribed number of puffs or nebulized doses, typically through a mouthpiece, following the device’s instructions. Proper inhalation technique—slow, deep breaths and holding the breath briefly—maximizes drug deposition in the lungs.
What are the most serious risks associated with Naos?+
Serious adverse events, although rare, include paradoxical bronchospasm, severe allergic reactions such as angioedema or anaphylaxis, significant tachycardia or arrhythmias, and marked drops in blood potassium (hypokalemia). Patients should seek immediate medical attention if they experience sudden worsening of breathing, swelling of the face or throat, or rapid, irregular heartbeats.
Who should not use Naos?+
Naos is contraindicated in individuals with known hypersensitivity to salbutamol, ipratropium, or any excipients in the formulation. It should also be avoided in patients with a history of severe paradoxical bronchospasm after inhaled bronchodilator use. Clinicians must assess each patient’s medical history before prescribing.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Salbutamol Sulfate, Ipratropium Bromide
Route
Inhalation Use
Manufacturer
Neopharmed Gentili Spa
Origin
EU

Related products

Almeida

Almeida

Salbutamol Sulfate, Ipratropium Bromide

I.B.N. Savio S.R.L.
EU
Berovent

Berovent

Salbutamol Sulfate, Ipratropium Bromide

Boehringer Ingelheim Hellas Single Member S.A.
EU
Biwind

Biwind

Salbutamol Sulfate, Ipratropium Bromide

Neopharmed Gentili Spa
EU
Butapral

Butapral

Salbutamol Sulfate, Ipratropium Bromide

Genetic Spa
EU